<DOC>
	<DOCNO>NCT01983683</DOCNO>
	<brief_summary>This clinical study conduct assess efficacy cadazolid compare vancomycin subject Clostridium difficile-associated diarrhea ( CDAD ) .</brief_summary>
	<brief_title>Efficacy Safety Cadazolid Versus Vancomycin Subjects With Clostridium Difficile-associated Diarrhea</brief_title>
	<detailed_description>Subjects select participate study treat either cadazolid vancomycin 10 day . At end treatment , clinical cure assess ; subject followed-up assess disease recurrence .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Signed Informed Consent . Male female â‰¥ 18 year age . Females childbearing potential must agree use adequate reliable method contraception . Subject diagnosis mildmoderate severe CDAD ( first occurrence first recurrence within 3 month ) : Diarrhea : change bowel habit &gt; 3 liquid unformed bowel movement ( UBM ) within 24 hour prior randomization , AND Positive C. difficile toxin test stool sample produce within 72 hour prior randomization . More one previous episode CDAD 3month period prior randomization . Evidence lifethreatening fulminant CDAD . Likelihood death within 72 hour cause . History inflammatory colitides , chronic abdominal pain , chronic diarrhea . Antimicrobial treatment active CDAD administer &gt; 24 hour except metronidazole treatment failure ( MTF ) Known hypersensitivity contraindication study drug , oxazolidinones , quinolones . Unable unwilling comply protocol requirement . Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Clostridium difficile infection</keyword>
	<keyword>Post-antibiotic diarrhea</keyword>
</DOC>